Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus

Patrick G. Dean, Joseph Peter Grande, Sanjeev M Sethi, Walter D. Park, Matthew D. Griffin, Fernando G Cosio, Timothy S. Larson, Mark D Stegall

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Analysis of 1-year surveillance biopsies was carried out for kidney transplant recipients participating in a randomized trial comparing tacrolimus- and sirolimus-based immunosuppression. The analysis was restricted to recipients remaining on assigned regimen throughout the first posttransplant year. Biopsies from 57 of 84 (68%) tacrolimus-randomized recipients were compared with 38 of 81 (47%) of sirolimus-randomized recipients, the discrepancy being explained by a higher rate of sirolimus discontinuation for non-graft-related complications. Included recipients from the two groups did not differ for baseline characteristics or 1-year iothalamate clearance. Histologic analysis indicated no differences between the groups for glomerular, arterial/arteriolar, or acute interstitial abnormalities. There were, however, significantly higher mean scores in the tacrolimus group for interstitial fibrosis and tubular atrophy with a trend toward higher estimated percent interstitial fibrosis. The results indicate that sirolimus may be associated with reduced early graft fibrosis compared with tacrolimus. This potential benefit is offset by lower success rate in maintaining the regimen and was not accompanied by superior glomerular filtration rate at 1 year.

Original languageEnglish (US)
Pages (from-to)1212-1215
Number of pages4
JournalTransplantation
Volume85
Issue number8
DOIs
StatePublished - Apr 2008

Fingerprint

Tacrolimus
Sirolimus
Histology
Transplants
Kidney
Fibrosis
Iothalamic Acid
Biopsy
Therapeutics
Glomerular Filtration Rate
Immunosuppression
Atrophy

Keywords

  • Calcineurin inhibitor
  • Chronic allograft nephropathy
  • Histology
  • Kidney transplantation
  • Randomized clinical trial
  • Sirolimus

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. / Dean, Patrick G.; Grande, Joseph Peter; Sethi, Sanjeev M; Park, Walter D.; Griffin, Matthew D.; Cosio, Fernando G; Larson, Timothy S.; Stegall, Mark D.

In: Transplantation, Vol. 85, No. 8, 04.2008, p. 1212-1215.

Research output: Contribution to journalArticle

Dean, Patrick G. ; Grande, Joseph Peter ; Sethi, Sanjeev M ; Park, Walter D. ; Griffin, Matthew D. ; Cosio, Fernando G ; Larson, Timothy S. ; Stegall, Mark D. / Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. In: Transplantation. 2008 ; Vol. 85, No. 8. pp. 1212-1215.
@article{5f951eb293e64b428277738e5cbd7f15,
title = "Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus",
abstract = "Analysis of 1-year surveillance biopsies was carried out for kidney transplant recipients participating in a randomized trial comparing tacrolimus- and sirolimus-based immunosuppression. The analysis was restricted to recipients remaining on assigned regimen throughout the first posttransplant year. Biopsies from 57 of 84 (68{\%}) tacrolimus-randomized recipients were compared with 38 of 81 (47{\%}) of sirolimus-randomized recipients, the discrepancy being explained by a higher rate of sirolimus discontinuation for non-graft-related complications. Included recipients from the two groups did not differ for baseline characteristics or 1-year iothalamate clearance. Histologic analysis indicated no differences between the groups for glomerular, arterial/arteriolar, or acute interstitial abnormalities. There were, however, significantly higher mean scores in the tacrolimus group for interstitial fibrosis and tubular atrophy with a trend toward higher estimated percent interstitial fibrosis. The results indicate that sirolimus may be associated with reduced early graft fibrosis compared with tacrolimus. This potential benefit is offset by lower success rate in maintaining the regimen and was not accompanied by superior glomerular filtration rate at 1 year.",
keywords = "Calcineurin inhibitor, Chronic allograft nephropathy, Histology, Kidney transplantation, Randomized clinical trial, Sirolimus",
author = "Dean, {Patrick G.} and Grande, {Joseph Peter} and Sethi, {Sanjeev M} and Park, {Walter D.} and Griffin, {Matthew D.} and Cosio, {Fernando G} and Larson, {Timothy S.} and Stegall, {Mark D}",
year = "2008",
month = "4",
doi = "10.1097/TP.0b013e31816a8ae6",
language = "English (US)",
volume = "85",
pages = "1212--1215",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus

AU - Dean, Patrick G.

AU - Grande, Joseph Peter

AU - Sethi, Sanjeev M

AU - Park, Walter D.

AU - Griffin, Matthew D.

AU - Cosio, Fernando G

AU - Larson, Timothy S.

AU - Stegall, Mark D

PY - 2008/4

Y1 - 2008/4

N2 - Analysis of 1-year surveillance biopsies was carried out for kidney transplant recipients participating in a randomized trial comparing tacrolimus- and sirolimus-based immunosuppression. The analysis was restricted to recipients remaining on assigned regimen throughout the first posttransplant year. Biopsies from 57 of 84 (68%) tacrolimus-randomized recipients were compared with 38 of 81 (47%) of sirolimus-randomized recipients, the discrepancy being explained by a higher rate of sirolimus discontinuation for non-graft-related complications. Included recipients from the two groups did not differ for baseline characteristics or 1-year iothalamate clearance. Histologic analysis indicated no differences between the groups for glomerular, arterial/arteriolar, or acute interstitial abnormalities. There were, however, significantly higher mean scores in the tacrolimus group for interstitial fibrosis and tubular atrophy with a trend toward higher estimated percent interstitial fibrosis. The results indicate that sirolimus may be associated with reduced early graft fibrosis compared with tacrolimus. This potential benefit is offset by lower success rate in maintaining the regimen and was not accompanied by superior glomerular filtration rate at 1 year.

AB - Analysis of 1-year surveillance biopsies was carried out for kidney transplant recipients participating in a randomized trial comparing tacrolimus- and sirolimus-based immunosuppression. The analysis was restricted to recipients remaining on assigned regimen throughout the first posttransplant year. Biopsies from 57 of 84 (68%) tacrolimus-randomized recipients were compared with 38 of 81 (47%) of sirolimus-randomized recipients, the discrepancy being explained by a higher rate of sirolimus discontinuation for non-graft-related complications. Included recipients from the two groups did not differ for baseline characteristics or 1-year iothalamate clearance. Histologic analysis indicated no differences between the groups for glomerular, arterial/arteriolar, or acute interstitial abnormalities. There were, however, significantly higher mean scores in the tacrolimus group for interstitial fibrosis and tubular atrophy with a trend toward higher estimated percent interstitial fibrosis. The results indicate that sirolimus may be associated with reduced early graft fibrosis compared with tacrolimus. This potential benefit is offset by lower success rate in maintaining the regimen and was not accompanied by superior glomerular filtration rate at 1 year.

KW - Calcineurin inhibitor

KW - Chronic allograft nephropathy

KW - Histology

KW - Kidney transplantation

KW - Randomized clinical trial

KW - Sirolimus

UR - http://www.scopus.com/inward/record.url?scp=42549102730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42549102730&partnerID=8YFLogxK

U2 - 10.1097/TP.0b013e31816a8ae6

DO - 10.1097/TP.0b013e31816a8ae6

M3 - Article

VL - 85

SP - 1212

EP - 1215

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 8

ER -